Products for Research Use Only

Atracurium

CAT: 0804-HY-B0292Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0292Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation[1][2][3][4][5].
CAS Number
64228-79-1
Product Name Alternative
BW-33A (free acid)
UNSPSC
12352005
Target
NAChR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/atracurium.html
Solubility
10 mM in DMSO
Smiles
O=C(OCCCCCOC(CC[N+]1(C)C(CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N+]4(C)C(CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4
Molecular Formula
C53H72N2O12+2
Molecular Weight
929.14
References & Citations
[1]Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A) : a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61 (9) :723-9.|[2]Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151 (5) :1537-42.|[3]Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18 (9) :599-604.|[4]Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7 (1) :459-72.|[5]Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95 (1) :9-14.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched